Cooley's 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024 | Cooley LLP

In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. While the year saw...

Related Keywords

Germany ,United States ,German ,American ,Concentra Biosciences ,Bristol Myer Squibb ,Dechra Pharma ,Astrazeneca ,Syneos Health ,Merck Kga ,Care Health ,Novartis ,Pfizer ,Merck Kgaa ,Amgen ,Bristol Myers Squibb ,American Association For Cancer Research ,Cerevel Therapeutics ,Gracell Biotechnologies ,Carmot Therapeutics ,Horizon Therapeutics ,Federal Trade Commission ,American Association ,Cancer Research ,Option Care Health ,Revolution Medicines ,Elliott Investment Management ,Patient Square Capital ,Veritas Capital ,Tang Capital Partners ,Tang Capital ,